Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease.
Detection
Hepatocellular cancer
Lipidomics
Metabolic (dysfunction) associated fatty liver disease
Metabolomics
Survival
Journal
Liver cancer
ISSN: 2235-1795
Titre abrégé: Liver Cancer
Pays: Switzerland
ID NLM: 101597993
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
06
08
2021
accepted:
25
06
2022
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
The burden of metabolic (dysfunction) associated fatty liver disease (MAFLD) is rising mirrored by an increase in hepatocellular cancer (HCC). MAFLD and its sequelae are characterized by perturbations in lipid handling, inflammation, and mitochondrial damage. The profile of circulating lipid and small molecule metabolites with the development of HCC is poorly characterized in MAFLD and could be used in future studies as a biomarker for HCC. We assessed the profile of 273 lipid and small molecule metabolites by ultra-performance liquid chromatography coupled to high-resolution mass spectrometry in serum from patients with MAFLD ( Twenty lipid species and one metabolite, reflecting changes in mitochondrial function and sphingolipid metabolism, were associated with the presence of cancer on a background of MAFLD with high accuracy (AUC 0.789, 95% CI: 0.721-0.858), which was enhanced with the addition of cirrhosis to the model (AUC 0.855, 95% CI: 0.793-0.917). In particular, the presence of these metabolites was associated with cirrhosis in the MAFLD subgroup ( These exploratory findings reveal a metabolic signature in serum which is capable of accurately detecting the presence of HCC on a background of MAFLD. This unique serum signature will be taken forward for further investigation of diagnostic performance as biomarker of early stage HCC in patients with MAFLD in the future.
Identifiants
pubmed: 36872928
doi: 10.1159/000525911
pii: lic-0012-0019
pmc: PMC9982340
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19-31Subventions
Organisme : Cancer Research UK
ID : 26813
Pays : United Kingdom
Informations de copyright
Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
Augusto Villanueva is an Editorial Board Member of Liver Cancer. Rohini Sharma received lecture fees from Bayer Healthcare and Shingoi; consulting fees from EISAI, Roche, SIRTEX; and research funding (to institution) from Incyte, Boston Scientific, AAA, and Astex Pharmaceuticals. Haonan Lu, Jacob George, Mohammed Eslam, Luigi Bolondi, Helen L. Reeves, Misti McCain, Edward Chambers, Caroline Ward, Dewi Sartika, Caroline Sands, Lynn Maslen, Matthew R. Lewis, and Ramya Ramaswami have no conflicts of interest to disclose.
Références
Nat Biotechnol. 2012 Oct;30(10):918-20
pubmed: 23051804
Anal Chem. 2013 Sep 3;85(17):8326-33
pubmed: 23889541
Metabolism. 2011 Jun;60(6):776-81
pubmed: 20869086
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Hepatology. 2004 Jul;40(1):185-94
pubmed: 15239102
Eur J Obstet Gynecol Reprod Biol. 2005 Feb 1;118(2):241-5
pubmed: 15653212
Nat Rev Cancer. 2018 Jan;18(1):33-50
pubmed: 29147025
Nat Rev Mol Cell Biol. 2018 Mar;19(3):175-191
pubmed: 29165427
J Lipid Res. 2015 Mar;56(3):722-736
pubmed: 25598080
J Investig Med. 2015 Oct;63(7):871-7
pubmed: 26244718
Cancer Res. 2014 Dec 1;74(23):6867-77
pubmed: 25267063
JAMA Oncol. 2017 Dec 1;3(12):1683-1691
pubmed: 28983565
Nature. 1996 Jun 27;381(6585):800-3
pubmed: 8657285
Anal Chem. 2016 Sep 20;88(18):9004-13
pubmed: 27479709
World J Gastroenterol. 2015 May 7;21(17):5131-7
pubmed: 25954086
Dig Dis Sci. 2014 Feb;59(2):365-74
pubmed: 24048683
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Nat Rev Cancer. 2013 Jan;13(1):51-65
pubmed: 23235911
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2022 Jan;76(1):195-201
pubmed: 34508791
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Lipid Res. 2018 Oct;59(10):1977-1986
pubmed: 30042157
FEBS J. 2018 Oct;285(20):3835-3848
pubmed: 30106227
Biochim Biophys Acta. 2016 Nov;1861(11):1767-1774
pubmed: 27570113
J Biol Chem. 2009 Jan 2;284(1):1-5
pubmed: 18718904
Cancer Res. 2016 May 15;76(10):2912-20
pubmed: 26976432
Electrophoresis. 2013 Oct;34(19):2848-56
pubmed: 24228263
Mol Carcinog. 2019 May;58(5):749-759
pubmed: 30604893
Int J Mol Sci. 2019 Dec 19;21(1):
pubmed: 31861664
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2
pubmed: 23041539
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Hepatology. 2009 Dec;50(6):1827-38
pubmed: 19937697
J Biol Chem. 2006 Apr 28;281(17):12093-101
pubmed: 16505490
Science. 1998 Mar 6;279(5356):1552-5
pubmed: 9488656
Gut. 2018 Aug;67(8):1493-1504
pubmed: 29437870
Lancet Oncol. 2007 Oct;8(10):889-97
pubmed: 17851129
Semin Liver Dis. 2008 Nov;28(4):360-9
pubmed: 18956292
J Hepatol. 2018 Feb;68(2):280-295
pubmed: 29154964
J Hepatol. 2014 Jan;60(1):110-7
pubmed: 23978719
Bioinformatics. 2019 Dec 15;35(24):5359-5360
pubmed: 31350543
Hepatology. 2021 Mar;73(3):1028-1044
pubmed: 32460431
J Biochem. 1995 Feb;117(2):237-8
pubmed: 7608105
Electrophoresis. 2013 Oct;34(19):2910-7
pubmed: 23856972
Diabetes Obes Metab. 2018 Dec;20(12):2800-2810
pubmed: 29974637
J Hepatol. 2013 Aug;59(2):292-9
pubmed: 23567080
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
Sci Rep. 2019 Jul 23;9(1):10663
pubmed: 31337855